Brokerages predict that Fate Therapeutics Inc (NASDAQ:FATE) will post sales of $1.02 million for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Fate Therapeutics’ earnings. The highest sales estimate is $1.03 million and the lowest is $1.00 million. Fate Therapeutics reported sales of $1.03 million in the same quarter last year, which would suggest a negative year over year growth rate of 1%. The business is expected to report its next quarterly earnings report on Thursday, March 15th.
On average, analysts expect that Fate Therapeutics will report full year sales of $1.02 million for the current year, with estimates ranging from $4.00 million to $4.11 million. For the next fiscal year, analysts anticipate that the business will report sales of $5.66 million per share, with estimates ranging from $4.02 million to $12.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that cover Fate Therapeutics.
Fate Therapeutics (NASDAQ:FATE) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.01). The firm had revenue of $1.03 million during the quarter, compared to analysts’ expectations of $0.95 million. Fate Therapeutics had a negative net margin of 935.09% and a negative return on equity of 64.55%. The business’s revenue for the quarter was up .0% on a year-over-year basis.
Fate Therapeutics (NASDAQ FATE) opened at $6.70 on Thursday. The stock has a market cap of $341.58, a PE ratio of -7.05 and a beta of 1.52. The company has a quick ratio of 7.21, a current ratio of 7.21 and a debt-to-equity ratio of 0.32. Fate Therapeutics has a 1-year low of $2.52 and a 1-year high of $7.25.
In other news, General Counsel Cindy Tahl sold 8,091 shares of the stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $3.85, for a total transaction of $31,150.35. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Daniel D. Shoemaker sold 13,225 shares of the stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $3.87, for a total transaction of $51,180.75. The disclosure for this sale can be found here. Corporate insiders own 10.88% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the stock. New York State Common Retirement Fund acquired a new stake in Fate Therapeutics during the 2nd quarter worth approximately $131,000. Rhumbline Advisers acquired a new stake in Fate Therapeutics during the 2nd quarter worth approximately $133,000. Hochman Cole Investment Advisors Inc. acquired a new stake in Fate Therapeutics during the 3rd quarter worth approximately $158,000. Schwab Charles Investment Management Inc. acquired a new stake in Fate Therapeutics during the 2nd quarter worth approximately $214,000. Finally, California State Teachers Retirement System acquired a new stake in Fate Therapeutics during the 2nd quarter worth approximately $219,000. 49.85% of the stock is owned by hedge funds and other institutional investors.
About Fate Therapeutics
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.